Advancing Science, Improving Lives
Bayer Pharmaceuticals transforms patient care through scientific innovation, strategic partnerships, and a robust pipeline focused on areas of high unmet medical need. With a renewed growth trajectory, Bayer delivers meaningful health solutions globally, driven by a clear strategy, operational excellence, and a deep commitment to patient welfare.
Key Figures
- Pipeline: 31 projects in clinical development
- Global reach: 93 countries served
- Experience: 148 years in pharmaceuticals
- Collaboration: More than 30 active partnerships
About Bayer Pharmaceuticals
Bayer Pharmaceuticals is a global leader in healthcare, dedicated to advancing science for a better life. Our mission is to address some of the world’s most pressing health challenges by developing innovative therapies and solutions that improve patient outcomes and quality of life. Our approach is grounded in scientific rigor, partnership, and a relentless focus on patient needs.
Our Strategic Focus
Meeting Unmet Medical Needs
We focus on therapeutic areas where the need is greatest, including cardiovascular diseases, oncology, women’s health, and rare conditions. Our late-stage pipeline is robust, with a balanced mix of small molecules and biologics, and a strong emphasis on precision medicine and advanced therapies.
Innovation Through Partnerships
Bayer’s growth is powered by a partnership-driven innovation strategy. We collaborate with leading academic institutions, biotechnology companies, and technology partners worldwide to accelerate the discovery and development of new therapies. Our flexible collaboration models enable early-stage co-creation, expanding access to external science while maintaining capital discipline.
Harnessing Artificial Intelligence
We are integrating artificial intelligence (AI) across the pharmaceutical value chain to accelerate clinical development, improve operational efficiency, and enhance decision-making. AI-driven approaches help us identify new drug targets, optimize clinical trials, and bring therapies to patients faster.
Our Impact on Patients
Bayer is advancing care in cardiovascular and renal diseases by leveraging genetics, biomarkers, and data science to develop targeted therapies. Our integrated research and commercial capabilities ensure that scientific breakthroughs translate rapidly into patient benefit, addressing conditions with significant unmet needs.
Our ambition is to improve and extend the lives of people living with cancer. We focus on developing therapies for challenging tumor types, including genitourinary, gastrointestinal, and lung cancers. By combining internal research excellence with external innovation, we strive to deliver transformative medicines that address critical gaps in cancer care.
Bayer is a longstanding leader in women’s health, committed to broadening access to effective solutions across the lifespan. Our portfolio addresses key needs in birth control, menopause management, and gynecological diseases, with a focus on improving quality of life for women worldwide.
We are at the forefront of cell and gene therapies, developing advanced treatments that move beyond symptom management to potentially modifying or curing diseases. Our comprehensive platform spans gene editing, gene augmentation, and cell-based therapies, supported by advanced manufacturing and global supply capabilities.
Bayer’s radiology business supports accurate diagnosis and treatment planning through innovative imaging solutions. Our portfolio includes contrast media, devices, and software, with ongoing investments in molecular imaging to enhance diagnostic precision and patient outcomes.
Our Research and Development Pipeline
Bayer Pharmaceuticals maintains a robust and diverse pipeline, with more than 30 projects in late-stage clinical development. Our research focuses on areas of high unmet medical need, including Oncology, Cardiology and Neurology, Women’s Health, Cell and Gene Therapies, and other specialty areas.
Our pipeline is balanced, with approximately 55% small molecules and the remainder biologics and advanced therapies. This diversity enables us to address a wide range of diseases and patient needs.
Pipeline Snapshot (as of January 2026):
- Number of active programs: 40
- Therapy area focus: Oncology, Cardiology/Neurology, Women’s Health, Cell & Gene Therapy
- Innovation mix: ~55% small molecules, ~45% biologics and advanced therapies
This overview reflects Bayer’s commitment to advancing science and delivering new solutions for patients worldwide, while maintaining the highest standards of scientific integrity and regulatory compliance.
Looking Ahead
Bayer Pharmaceuticals is poised for continued growth, with a strong pipeline, a focus on high-impact innovation, and a commitment to patient-centered care. By combining scientific leadership, strategic partnerships, and operational excellence, we aim to deliver sustained value for patients, healthcare professionals, and society.
